SCHEMBL24252269

SCHEMBL24252269

COc1ccc(B(O)O)cc1-c1ccc2c(N)nnc(C)c2c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DHFR P00374 5/20 0.40
MAP4K4 O95819 1/20 0.37
PLAU P00749 3/20 0.34
PLG P00747 3/20 0.34
FYN P06241 3/20 0.33
F12 P00748 1/20 0.33
F11 P03951 1/20 0.33
KLKB1 P03952 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
CHEK2 O96017 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
LRRK2 Q5S007 1/20 0.33
LIMK1 P53667 1/20 0.33
PLAT P00750 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25242412 0.94 DHFR (0.37) DHFRMAP4K4PLAUPLGFYN
Formic Acid SCHEMBL30451288 0.94 DHFR (0.37) DHFRMAP4K4PLAUPLGFYN
SCHEMBL26771008 0.92 DHFR (0.40) DHFRMAP4K4PLAUPLGFYN
SCHEMBL25242410 0.87 DHFR (0.36) DHFRMAP4K4PLAUPLGFYN
SCHEMBL24252678 0.87 KDR (0.37) DHFRPLGF12F11KLKB1
SCHEMBL24252712 0.86 SCN9A (0.32) PLGF12F11KLKB1PRSS1
SCHEMBL30452320 0.86 SCN9A (0.36) PLGF12F11KLKB1PRSS1
SCHEMBL24252504 0.86 SCN9A (0.36) PLGF12F11KLKB1PRSS1
SCHEMBL24252940 0.86 ALOX5AP (0.35) DHFRPLGF12F11KLKB1
SCHEMBL24252263 0.85 MAP4K4 (0.37) MAP4K4PLGF12F11KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 DHFR 1380/4885MAP4K4 2769/4885PLAU 381/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 DHFR 1380/4885MAP4K4 2769/4885PLAU 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.